Skip to main content
. 2015 Sep 1;48(1):162–170. doi: 10.4143/crt.2015.017

Table 1.

Patient characteristics (n=42)

Characteristic No. of patients (%)
Sex
 Male 20 (47.6)
 Female 22 (52.4)
Median age (range, yr) 63 (30-81)
Treatment setting of imatinib
 Neoadjuvant 8 (19.0)
 Adjuvant 11 (26.2)
 Palliative 23 (54.8)
Imatinib dose at the time of skin rash (mg)
 800 1 (2.4)
 600 1 (2.4)
 400 38 (90.5)
 300 2 (4.8)
Grade of skin rash
 3 40 (95.2)
 4 2 (4.8)